CNS Pharmacology: Drugs for Parkinson’s Disease

Introduction/Overview

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized primarily by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor manifestations such as bradykinesia, rest tremor, rigidity, and postural instability. The prevalence of PD increases markedly with age, affecting approximately 1–2% of individuals over 60 years of age, and substantially impacting quality of life and health care resources. A deep understanding of the pharmacologic agents employed in PD management is essential for clinicians, as therapeutic decisions must balance efficacy, side‑effect profiles, and individual patient characteristics. This chapter provides a systematic review of the principal drug classes used in PD, delineating their mechanisms of action, pharmacokinetic properties, clinical applications, adverse effect spectra, interaction potentials, and special patient considerations. The information herein is intended to support evidence‑based decision making in clinical practice and to serve as a foundation for advanced study in pharmacotherapy.

• Describe the pathophysiologic basis for pharmacologic intervention in Parkinson’s disease.
• Identify and classify the main drug classes used in PD management.
• Explain the pharmacodynamic and pharmacokinetic principles underlying each therapeutic agent.
• Recognize common and serious adverse effects, and understand strategies for mitigation.
• Assess drug‑drug interactions and special considerations for vulnerable populations.

Classification

Dopamine Precursor Therapy (Levodopa/Carbidopa)

Levodopa, the active metabolite of L‑DOPA, is the most potent symptomatic agent for PD. Carbidopa, a peripheral dopa decarboxylase inhibitor, is co‑administered to enhance central availability and reduce peripheral side effects. The combination is available in various fixed‑dose formulations, including immediate‑release, controlled‑release, and extended‑release preparations. Levodopa remains the cornerstone of PD pharmacotherapy, particularly in early to moderate disease stages.

Dopamine Agonists

Dopamine agonists directly stimulate dopaminergic receptors, mimicking the action of endogenous dopamine. These agents are subdivided into long‑acting (e.g., pramipexole, ropinirole, rotigotine) and short‑acting (e.g., apomorphine, pramipexole) formulations. They are often used as adjuncts to levodopa or as monotherapy in younger patients to delay motor complications associated with levodopa therapy.

Monoamine Oxidase B Inhibitors (MAO‑B Inhibitors)

MAO‑B inhibitors, such as selegiline and rasagiline, selectively inhibit the oxidative deamination of dopamine, thereby prolonging its synaptic availability. They are commonly prescribed in early disease or as adjuncts to levodopa to reduce motor fluctuations.

Catechol‑O‑Methyltransferase Inhibitors (COMT Inhibitors)

COMT inhibitors, including entacapone and opicapone, block the peripheral metabolism of levodopa to 3‑O‑methyldopa, enhancing levodopa bioavailability and smoothing motor symptoms. They are typically used in combination with levodopa/carbidopa regimens in patients experiencing “wear‑off” phenomena.

Anticholinergic Agents

Anticholinergic drugs such as benztropine and trihexyphenidyl reduce cholinergic activity in the basal ganglia, thereby ameliorating tremor and dystonia. Their use is largely limited to younger patients due to cognitive side effect profiles.

Amantadine and NMDA Receptor Antagonists

Amantadine, originally an antiviral agent, exhibits dopaminergic and NMDA receptor antagonist properties. It is effective in reducing dyskinesias and early motor symptoms, and may have neuroprotective roles in some experimental models.

Other Emerging Therapies

Recent advances include gene therapy approaches, extended‑release levodopa formulations, and novel non‑dopaminergic agents targeting serotonergic, glutamatergic, and adrenergic pathways. These therapies are still under investigation or limited to specialized clinical settings.

Mechanism of Action

Levodopa/Carbidopa

Levodopa is a precursor that crosses the blood‑brain barrier via large neutral amino acid transporters. Inside the CNS, it is decarboxylated by aromatic L‑amino acid decarboxylase to dopamine, which then binds to dopamine receptors (D1‑D5). The resultant stimulation of postsynaptic dopaminergic pathways restores motor function. Carbidopa, minimally permeable to the CNS, inhibits peripheral decarboxylation, thereby increasing levodopa’s central concentration and reducing peripheral adverse effects such as nausea and orthostatic hypotension.

Dopamine Agonists

Dopamine agonists bind with high affinity to D2‑like receptors (primarily D2, D3, and D4 subtypes) in the nigrostriatal pathway. They also exhibit partial agonist activity at serotonergic 5‑HT1A receptors, which may contribute to their therapeutic profile. The direct receptor activation bypasses the need for conversion to dopamine, allowing for a more predictable pharmacodynamic response. Long‑acting formulations achieve sustained receptor occupancy, reducing the need for frequent dosing.

MAO‑B Inhibitors

MAO‑B is an intracellular enzyme responsible for the oxidative deamination of dopamine within presynaptic terminals. Inhibition by selegiline or rasagiline leads to increased synaptic dopamine levels, thereby enhancing dopaminergic transmission. Selectivity for MAO‑B minimizes interactions with dietary tyramine, reducing the risk of hypertensive crises.

COMT Inhibitors

COMT catalyzes the methylation of levodopa to 3‑O‑methyldopa, an inactive metabolite. Inhibition by entacapone or opicapone reduces this peripheral metabolism, enhancing the proportion of levodopa reaching the CNS. The increased bioavailability translates to smoother motor control and reduced “off” periods.

Anticholinergic Agents

Benztropine and trihexyphenidyl antagonize muscarinic acetylcholine receptors (primarily M1–M3 subtypes) in the striatum. By reducing cholinergic overactivity relative to dopaminergic activity, these agents help rebalance basal ganglia circuitry, which is particularly effective in tremor and rigidity.

Amantadine

Amantadine increases dopamine release, blocks dopamine reuptake, and antagonizes NMDA glutamate receptors. The combined dopaminergic and glutamatergic modulation contributes to its efficacy in reducing dyskinesias and improving early motor symptoms. The mechanism underlying its neuroprotective potential remains under investigation, with evidence suggesting attenuation of excitotoxic neuronal injury via NMDA blockade.

Pharmacokinetics

Levodopa/Carbidopa

Levodopa is well absorbed orally, with peak plasma concentrations occurring within 30–60 minutes. Its bioavailability is limited by peripheral metabolism; carbidopa significantly enhances central availability by inhibiting peripheral decarboxylation. Distribution is extensive, with a volume of distribution approximating 0.8–1.0 L/kg. Metabolism occurs primarily via peripheral decarboxylation and COMT-mediated methylation. Excretion is mainly renal, with a half‑life of 1–2 hours for levodopa alone and 3–4 hours when combined with carbidopa. Dose adjustments may be necessary in renal impairment; hepatic metabolism is not a major route, so hepatic dysfunction has limited impact.

Dopamine Agonists

Pramipexole and ropinirole are orally administered with bioavailability exceeding 80%, reaching peak plasma concentrations within 1–2 hours. Their distribution is moderate; plasma protein binding ranges from 30–50%. Metabolism occurs via glucuronidation and CYP450 enzymes, with renal excretion predominating. Half‑lives vary by agent: pramipexole 6–7 hours, ropinirole 6–8 hours, and apomorphine 1–2 hours (intravenous). Long‑acting formulations extend systemic exposure, often requiring lower daily doses.

MAO‑B Inhibitors

Selegiline is rapidly absorbed, with peak concentrations after 1–2 hours. It undergoes hepatic metabolism to active metabolites (R‑enantiomers) and inactive metabolites; renal excretion accounts for a significant fraction. The half‑life of selegiline is approximately 1–2 days, whereas rasagiline has a shorter half‑life (~1 day) but is a mechanism‑based irreversible inhibitor of MAO‑B, leading to sustained enzyme inactivation. Both agents are well tolerated in hepatic impairment, though dosage adjustments are advisable in severe renal dysfunction.

COMT Inhibitors

Entacapone is absorbed rapidly, with peak plasma levels within 30 minutes. It is extensively metabolized via glucuronidation, and its metabolites are renally excreted. The half‑life of entacapone is approximately 1 hour, necessitating dosing immediately before levodopa administration. Opicapone, a third‑generation COMT inhibitor, has a longer half‑life (~12 hours), permitting once‑daily dosing. Both agents are contraindicated in severe hepatic impairment due to reduced glucuronidation capacity.

Anticholinergic Agents

Benztropine is highly lipophilic, achieving a large volume of distribution and crossing the blood‑brain barrier efficiently. Oral absorption is rapid, with peak concentrations in 1–2 hours. Metabolism occurs in the liver via CYP2D6 and CYP3A4, and excretion is primarily biliary. The half‑life ranges from 16–20 hours, necessitating cautious dosing in elderly patients to avoid accumulation. Trihexyphenidyl is similarly lipophilic, with a half‑life of 12–14 hours, and is primarily metabolized hepatically.

Amantadine

Orally administered amantadine is absorbed with peak plasma levels at 2–4 hours. Distribution is extensive, with a volume of distribution of ~25 L. Metabolism is minimal; the drug is largely excreted unchanged by the kidneys. The half‑life is approximately 10–20 hours, requiring adjustments in renal insufficiency. The drug’s excretion profile makes it suitable for patients with hepatic dysfunction, though caution remains warranted in severe renal disease.

Therapeutic Uses/Clinical Applications

Levodopa/Carbidopa

Primary indication is symptomatic relief of motor deficits in all stages of PD. It is also used in patients with early disease to delay the onset of motor complications and in advanced stages to manage “off” periods. The combination is effective in reducing rigidity, bradykinesia, and tremor, and in improving gait and balance. Off‑label uses include the treatment of atypical parkinsonism, though efficacy is variable.

Dopamine Agonists

Indicated as monotherapy in early, younger patients (<65 years) to postpone the emergence of levodopa‑related motor complications. They are also employed as adjuncts to levodopa in moderate to advanced disease to reduce dosage requirements and mitigate dyskinesias. Off‑label applications include augmentation of levodopa therapy in patients with motor fluctuations and as a therapeutic option for patients intolerant to levodopa.

MAO‑B Inhibitors

Used in early disease to enhance dopaminergic transmission and delay motor complications. They are also prescribed in combination with levodopa to smooth motor fluctuations and reduce “wear‑off” episodes. Off‑label use in Parkinsonism secondary to other etiologies is infrequent and generally reserved for clinical trials.

COMT Inhibitors

Primarily utilized as adjuncts to levodopa/carbidopa in patients experiencing motor fluctuations. They are recommended for patients with predictable “off” periods and for preemptive management of dyskinesias. Off‑label indications are limited to enhancing levodopa bioavailability in refractory cases.

Anticholinergic Agents

Employed in younger patients to address tremor and rigidity, particularly when levodopa is contraindicated or poorly tolerated. Off‑label uses include the management of drug‑induced parkinsonism and in patients with dystonic reactions.

Amantadine

Indicated for the treatment of dyskinesias in levodopa‑treated patients and for early motor symptoms. Off‑label applications include the management of cognitive deficits in PD and as an adjunct in patients with refractory motor fluctuations.

Other Emerging Therapies

These agents are not yet widely adopted; clinical trials are ongoing to evaluate efficacy and safety. Their use remains restricted to research settings or specialized clinical centers.

Adverse Effects

Levodopa/Carbidopa

Common side effects include nausea, vomiting, orthostatic hypotension, dyskinesias, and impulse control disorders. Serious adverse events encompass levodopa‑induced dyskinesias, neuroleptic malignant syndrome (rare), and severe orthostatic hypotension leading to falls. Black box warning: The risk of impulse control disorders (e.g., pathological gambling, hypersexuality, compulsive shopping) is emphasized, and patients should be monitored accordingly.

Dopamine Agonists

Typical adverse effects include nausea, somnolence, hallucinations, peripheral edema, and weight gain. Long‑acting agents may be associated with sleep‑walking, dream enactment, and sudden onset of sleep. Serious complications comprise neuroleptic malignant syndrome (rare), orthostatic hypotension, and impulse control disorders. Black box warning: Similar to levodopa, there is a risk of impulse control disorders and compulsive behaviors.

MAO‑B Inhibitors

Common adverse events are nausea, insomnia, and mild dizziness. Rare but serious events include hepatotoxicity, especially with selegiline, and serotonin syndrome when combined with serotonergic agents. No black box warning is currently issued for these agents.

COMT Inhibitors

Typical side effects include diarrhea, abdominal cramps, and black discoloration of urine and feces. Serious adverse events are uncommon but may involve severe gastrointestinal upset and, rarely, hepatic injury. No black box warning is present.

Anticholinergic Agents

Common adverse effects encompass dry mouth, blurred vision, urinary retention, constipation, and cognitive impairment (particularly in the elderly). Serious complications include delirium, hallucinations, and acute urinary retention. No black box warning is associated with these agents; however, caution is advised in patients with glaucoma or prostatic hypertrophy.

Amantadine

Typical adverse events are dizziness, insomnia, and nausea. Serious complications include neuropsychiatric reactions such as hallucinations, psychosis, and seizures, particularly in patients with renal impairment. No black box warning is currently issued, but monitoring for neuropsychiatric side effects is prudent.

Drug Interactions

Levodopa/Carbidopa

Concurrent use of anticholinergic agents, tricyclic antidepressants, and MAO‑A inhibitors can precipitate serotonin syndrome. Nonsteroidal anti‑inflammatory drugs (NSAIDs) may reduce levodopa absorption. Antibiotics such as rifampin can induce hepatic enzymes, lowering levodopa levels. Antipsychotics with dopamine‑blocking properties can antagonize levodopa efficacy.

Dopamine Agonists

Combination with serotonergic agents (SSRIs, SNRIs) increases the risk of serotonin syndrome. Antihypertensive drugs may exacerbate orthostatic hypotension. Antipsychotics can diminish dopaminergic agonist efficacy. Alcohol may potentiate central nervous system depressant effects.

MAO‑B Inhibitors

Concurrent use with serotonergic drugs (SSRIs, SNRIs, TCAs) raises the potential for serotonin syndrome. Careful monitoring is advised when combining with other CNS depressants. Antihypertensive agents may enhance orthostatic hypotension.

COMT Inhibitors

When combined with levodopa, COMT inhibitors can increase levodopa plasma concentrations, potentially enhancing the risk of dyskinesias. Anticholinergic agents may increase the incidence of constipation. Hepatic enzyme inducers (e.g., carbamazepine) can reduce COMT inhibitor efficacy.

Anticholinergic Agents

Co‑administration with other anticholinergic or antihistaminic drugs may amplify anticholinergic toxicity. Use with antipsychotics may worsen extrapyramidal side effects. Concomitant use with diuretics or antihypertensives may exacerbate orthostatic hypotension.

Amantadine

Combination with other dopamine‑enhancing agents may increase the likelihood of dyskinesias. Concomitant use with other CNS depressants can potentiate sedation. Co‑administration with lithium may increase neurotoxicity.

Special Considerations

Pregnancy and Lactation

Levodopa/carbidopa and dopamine agonists are classified as category C; data in humans are limited, and potential risks to the fetus cannot be excluded. MAO‑B inhibitors are also category C. COMT inhibitors and anticholinergic agents lack sufficient human data; their use is generally discouraged during pregnancy. Amantadine has limited human safety data; caution is advised. Lactation: Levodopa and dopamine agonists are excreted in breast milk in minimal amounts, but potential effects on the infant remain uncertain. Clinicians should weigh maternal benefits against potential fetal or infant exposures.

Pediatric and Geriatric Populations

Levodopa/carbidopa is the standard therapy in children with juvenile parkinsonism, though dosing must be carefully titrated. Dopamine agonists are generally avoided in children due to higher susceptibility to impulse control disorders. Geriatric patients require dose adjustments due to altered pharmacokinetics and increased sensitivity to orthostatic hypotension and cognitive side effects. Careful monitoring for falls, confusion, and medication interactions is essential.

Renal Impairment

Levodopa is primarily metabolized hepatically; however, renal excretion of metabolites necessitates dose monitoring in severe renal disease. Dopamine agonists, particularly pramipexole, are renally cleared and require dose reduction in creatinine clearance <30 mL/min. COMT inhibitors are largely renally eliminated; dose adjustments are recommended in renal insufficiency. Amantadine is renally excreted; dose reduction or avoidance is advised in severe renal impairment to prevent neurotoxicity.

Hepatic Impairment

Levodopa/carbidopa metabolism is minimally hepatic; mild to moderate hepatic impairment generally does not necessitate dose changes. MAO‑B inhibitors, COMT inhibitors, and anticholinergic agents undergo hepatic metabolism and may require cautious use or dose adjustment in severe hepatic disease. Amantadine is safe in hepatic impairment due to negligible hepatic metabolism.

Summary/Key Points

• Levodopa/carbidopa remains the most effective symptomatic therapy for PD, with efficacy dependent on central availability and peripheral metabolism.
• Dopamine agonists serve as monotherapy in younger patients and adjuncts in advanced disease; they offer a lower risk of motor complications but carry a distinct adverse event profile.
• MAO‑B and COMT inhibitors are valuable adjuncts that enhance levodopa bioavailability and reduce motor fluctuations, with relatively favorable safety profiles.
• Anticholinergic agents and amantadine are reserved for specific motor symptoms and dyskinesias, respectively, and require cautious use due to cognitive and neuropsychiatric risks.
• Drug‑drug interactions, especially involving serotonergic agents and CNS depressants, necessitate vigilant monitoring; renal and hepatic impairments guide dose adjustments.
• Clinical decision making should incorporate individual patient factors, disease stage, and comorbid conditions to optimize therapeutic outcomes while minimizing adverse effects.

In clinical practice, the therapeutic regimen for Parkinson’s disease is typically individualized, integrating multiple pharmacologic agents to address motor and non‑motor manifestations while mitigating complications associated with long‑term therapy. Ongoing research into disease‑modifying treatments and novel pharmacologic targets may further refine management strategies in the coming years.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.